Research
Immune System Disease
Fighting Ability
Study By UCSD Gives New Insight Into How Anthrax Bacteria
Can Evade A Host's Immune Response
1-7-2004
Biologists at the University of California, San Diego have
determined how toxin produced by anthrax bacteria blocks
a person's normal immune response, a discovery that could
lead to new treatments for anthrax infection. In a paper
to be published in the January 15th issue of The Journal
of Immunology the UCSD scientists show why, in the presence
of anthrax toxin, human immune cells fail to respond normally
to lipopolysaccharide--a component of the cell walls of
many bacteria including the bacteria that cause anthrax,
Bacillus anthracis. Bacterial invasion, or the presence
of lipopolysaccharide, usually causes immune cells known
as macrophages to release cytokines--chemicals that signal
other cells about the presence of an invader. Release of
cytokines causes large numbers of immune cells to arrive
at the site of infection and destroy the bacteria. By blocking
this host immune response, anthrax bacteria are able to
multiply unchecked. According to the Centers for Disease
Control, approximately 75 percent of people infected with
inhalation anthrax die, even with all possible supportive
care including appropriate antibiotics.
"Although
it was known for quite some time that anthrax toxins can
suppress cytokine production, the mechanism by which Bacillus
anthracis escapes the immune response isn't really understood,"
says Michael David, a biology professor at UCSD who headed
the research team. "We have identified a protein molecule
targeted by the anthrax toxin and determined where it acts
in the sequence of steps involved in immune response."
|
|
Macrophages have special receptors on their surfaces
that bind to lipopolysaccharide. The binding of lipopolysaccharide
to this receptor sets off a sequence of events inside the macrophage,
in which a series of proteins activate one another in turn. This cascade
of proteins activating one another ultimately turns on cytokine genes,
causing the macrophage to churn out large quantities of cytokines.
It turns out that there are two separate, sometimes
cooperating, routes in the cell by which series of proteins activate
one another to switch on production of cytokines. One of the routes
has been recognized for a long time, but researchers were sometimes
puzzled when cytokine production was turned on or off without the
proteins along this route being activated or deactivated. This puzzle
was resolved when the David group and other groups simultaneously
identified the second route, the IRF3 pathway. The anthrax toxin targets
the IRF3 pathway by cleaving MKK6--one of the proteins in the series
along the route. The cleavage of MKK6 prevents the cytokine genes
from being switched on.
When the researchers made mutant macrophages with
a variant of MKK6 that could not be cleaved by the anthrax toxin,
these macrophages responded to lipopolysaccharide by producing cytokines
even in the presence of the anthrax toxin. This suggests that developing
a drug that could protect MKK6 and prevent anthrax toxin from cleaving
it could help to prevent an anthrax infection from getting out of
control. The anthrax bacteria would be unable to evade the normal
immune response.
"While these results may not lead to a drug to
cure anthrax in the next six months, the more you understand about
bacteria and how they target the immune response the more options
you have for developing drugs to treat the infections," says
David.
Previous work by other researchers has suggested that
anthrax toxin evades the immune system by killing macrophages; however,
according to David, cell death does not fully explain how anthrax
bacteria evade the immune system.
"Only some types of macrophages are killed by
anthrax toxins, but anthrax toxins diminish the production of cytokines
in all of the macrophages we have tested," David explains. "Also,
less toxin is needed to shut off the immune response than to kill
the macrophages."
The other UCSD researchers involved with this project
were Oanh Dang, a former graduate student in the David laboratory
and the first author of the paper; Lorena Navarro, a former graduate
student in the David laboratory and first author on two other papers
that initially identified the IRF3 immune response pathway; and Keith
Anderson, a technician in the David laboratory. This work was supported
by a grant from the National Institutes of Health.
This story has been adapted from a news release issued
by University Of California - San Diego, www.ucsd.edu.
Next - Back
to Immune System Disease Fighting Ability Research